CDR3–Epitope Chemical Scoring for Autoimmune Disease Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating autoimmune diseases are inefficient and lack the ability to accurately distinguish between individuals with and without autoimmune diseases, and there is a need for improved computational analyses to monitor disease activity.
Innovation Solution
A method involving chemical complementarity scoring is used to determine the interaction between immunoglobulin heavy chain complementarity determining regions (CDR3) and autoimmune disease epitopes, utilizing electrostatic and hydrophobic interactions to identify and treat autoimmune diseases such as multiple sclerosis and celiac disease, through the administration of therapeutic agents when a specific complementarity score is increased.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current immunotherapy methods are used to treat autoimmune diseases, then treatment can be provided, but the ability to accurately distinguish patients with autoimmune diseases from healthy individuals is insufficient
Solution Approach 1:
The patent changes the parameter of measurement from general immune response assessment to specific electrostatic and hydrophobic interaction scoring between CDR3 regions and epitopes. By quantifying chemical complementarity scores and comparing them against control subjects, the method achieves more precise and reliable differentiation between autoimmune disease patients and healthy individuals.
2Productivity
If targeted immunotherapies blocking inflammatory cytokines and cell surface molecules are used, then pro-inflammatory signaling pathways are suppressed, but efficient computational analyses for diagnosis and disease monitoring remain challenging
Solution Approach 1:
The patent replaces complex computational immune repertoire analysis with a simplified electrostatic and hydrophobic interaction scoring system. By focusing on specific chemical properties (electrostatic potential, hydrophobicity) of CDR3-epitope interactions, the method maintains treatment effectiveness while reducing computational complexity for clinical diagnosis and monitoring.
3Reliability
If general autoimmune disease treatments are administered, then broad immune suppression is achieved, but the ability to monitor disease activity and distinguish affected individuals remains insufficient
Solution Approach 1:
The patent implements a feedback mechanism by calculating complementarity scores from patient samples and comparing them against control subjects. This scoring system provides quantitative feedback on disease presence and activity level, enabling reliable monitoring and distinction between affected and unaffected individuals through measurable electrostatic and hydrophobic interaction differences.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate diagnosis and treatment of autoimmune diseases by identifying increased complementarity scores, enabling targeted therapeutic interventions.
Implementation Method 1
determining a complementarity score (CS) between the IGH CDR3 and an epitope of the autoimmune disease, wherein the CS is based on electrostatic and hydrophobic interactions between the IGH CDR3 and the epitope
Implementation Method 2
determining a complementarity score (CS) between the IGH CDR3 and an epitope of the autoimmune disease, wherein the CS is based on electrostatic and hydrophobic interactions between the IGH CDR3 and the epitope
Data Source
AI summary
The present disclosure relates methods of treating, preventing, and/or diagnosing autoimmune diseases using chemical complementarity scoring.